Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia

Lai, Jasmine; Syngelaki, Argyro; Poon, Liona C.; Nucci, Marta; Nicolaides, Kypros H.

doi:10.1159/000343220

Cited by 19 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This research has already started. This issue of Fetal Diagnosis and Therapy publishes four studies performed by the Fetal Medicine Foundation which provide important evidence supporting that prediction of late-onset PE is possible by means of either uterine artery Doppler or angiogenic factors [9,10,11,12]. These results are in line with another very recent study from the United States [13].…”

supporting

confidence: 65%

Towards an Integrated Third-Trimester Screening in Pregnancy

Gratacós¹

2013

Fetal Diagn Ther

View full text Add to dashboard Cite

supporting

confidence: 65%

Towards an Integrated Third-Trimester Screening in Pregnancy

Gratacós¹

2013

Fetal Diagn Ther

View full text Add to dashboard Cite

“…First- and second-trimester strategies show poorer predictive values for late-onset forms of PE and IUGR [51,52,53,54,55,56,57]. This may be explained by the milder nature of the disease, where changes can possibly not be picked up that early in gestation, together with the heterogeneity of these clinical conditions late in pregnancy.…”

Section: Prediction Of Complications Of Placental Diseasementioning

confidence: 99%

“…Predictive values in the third trimester for late PE are superior to those achieved in the first or second trimester of pregnancy. In addition, several studies from the Fetal Medicine Foundation [55,56] have also evaluated the predictive value of angiogenic factors together with maternal characteristics and uterine Doppler in the third trimester for late PE. A combination of maternal characteristics and serum PlGF had a detection rate of 86 and 53% for intermediate PE (delivery at 34-37 weeks) and late PE (delivery after 37 weeks), with a 10% false-positive rate.…”

Section: Prediction Of Complications Of Placental Diseasementioning

confidence: 99%

Update on the Pathophysiological Implications and Clinical Role of Angiogenic Factors in Pregnancy

2015

View full text Add to dashboard Cite

Angiogenic markers are now being incorporated into clinical practice for the screening, diagnosing, and monitoring of preeclampsia. Pregnancy requires both vasculogenesis and angiogenesis in the fetal compartment and angiogenesis in the maternal compartment. Abnormal angiogenesis in the placenta determines impaired remodeling of the maternal spiral arteries and placental underperfusion that may ultimately lead to fetal growth restriction and maternal preeclampsia. The dysregulation of angiogenesis in the placenta and maternal-fetal circulation has emerged as one of the main pathophysiological features in the development of placental insufficiency and its clinical consequences. Abnormal angiogenesis has also been related to other obstetric and fetal conditions such as peripartum cardiomyopathy and fetal cardiac defects. This opens up new challenges for our understanding of angiogenic involvement in maternal cardiovascular function and fetal cardiac development, and it offers new clinical opportunities. This review summarizes the current knowledge of the pathophysiological implications and the clinical role of angiogenic factors in pregnancy.

show abstract

“…61 The predictive performance of biomarkers for late pre-eclampsia is improved if the evaluation is performed in the third trimester. 85,86 However, in most studies, the majority of patients with an imbalance between angiogenic and antiangiogenic factors do not subsequently develop pre-eclampsia. 81–87 Such tests, therefore, have low PPVs regardless of the timing of sample collection.…”

Section: Risk Assessment In Asymptomatic Womenmentioning

confidence: 99%

Pre-eclampsia part 2: prediction, prevention and management

et al. 2014

View full text Add to dashboard Cite

An antiangiogenic state might constitute a terminal pathway for the multiple aetiologies of pre-eclampsia, especially those resulting from placental abnormalities. The levels of angiogenic and antiangiogenic proteins in maternal blood change prior to a diagnosis of pre-eclampsia, correlate with disease severity and have prognostic value in identifying women who will develop maternal and/or perinatal complications. Potential interventions exist to ameliorate the imbalance of angiogenesis and, hence, might provide opportunities to improve maternal and/or perinatal outcomes in pre-eclampsia. Current strategies for managing pre-eclampsia consist of controlling hypertension, preventing seizures and timely delivery of the fetus. Prediction of pre-eclampsia in the first trimester is of great interest, as early administration of aspirin might reduce the risk of pre-eclampsia, albeit modestly. Combinations of biomarkers typically predict pre-eclampsia better than single biomarkers; however, the encouraging initial results of biomarker studies require external validation in other populations before they can be used to facilitate intervention in patients identified as at increased risk. Angiogenic and antiangiogenic factors might also be useful in triage of symptomatic patients with suspected pre-eclampsia, differentiating pre-eclampsia from exacerbations of pre-existing medical conditions and performing risk assessment in asymptomatic women. This Review article discusses the performance of predictive and prognostic biomarkers for pre-eclampsia, current strategies for preventing and managing the condition and its long-term consequences.

show abstract

Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia

Cited by 19 publications

References 24 publications

Towards an Integrated Third-Trimester Screening in Pregnancy

Towards an Integrated Third-Trimester Screening in Pregnancy

Update on the Pathophysiological Implications and Clinical Role of Angiogenic Factors in Pregnancy

Pre-eclampsia part 2: prediction, prevention and management

Contact Info

Product

Resources

About